Table 3.
Univariate Cox regression analysis results for association with time to MACE or time to ACM
| Variable | Time to MACE (n = 113) |
Time to ACM (n = 79) |
||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Demographics | ||||
| Age ≥ 75 y | 3.02 (2.07–4.40) | <.001 | 5.17 (3.31–8.07) | <.001 |
| Sex (female vs male) | 1.31 (0.87–1.97) | NS (P = .19) | ∗ | ∗ |
| BMI ≥ 30 | 1.30 (0.89–1.90) | NS (P = .18) | 1.40 (0.89–2.20) | NS (P = .14) |
| Medical history | ||||
| Hypertension | 1.82 (1.21–2.71) | .004 | 2.12 (1.29–3.49) | .003 |
| Hyperlipidemia | 1.56 (1.06–2.27) | .023 | 1.90 (1.20–3.02) | .007 |
| Diabetes mellitus | 2.56 (1.76–3.74) | <.001 | 2.77 (1.78–4.33) | <.001 |
| Ever smoked | 1.22 (0.80–1.86) | NS (P = .35) | 1.33 (0.80–2.21) | NS (P = .27) |
| CKD (Cr > 150) | 2.72 (1.65–4.47) | <.001 | 3.93 (2.34–6.61) | <.001 |
| COPD | 1.39 (0.79–2.43) | .26 | 1.88 (1.03–3.42) | .039 |
| Prior CVD | 3.06 (2.09–4.48) | <.001 | 4.25 (2.64–6.87) | <.001 |
| On statin before index admission | 1.66 (1.14–2.42) | .009 | 2.01 (1.26–3.21) | .003 |
| Diagnosis | ||||
| Raised vs normal troponin NSTE-ACS | 0.84 (0.34–2.09) | NS (P = .71) | 1.47 (0.36–6.01) | NS (P = .59) |
| Treatment | ||||
| PCI/CABG | 0.42 (0.28–0.63) | <.001 | 0.31 (0.18–0.53) | <.001 |
| Functional statin at V2 | ||||
| NYHA | 1.89 (1.51–2.37) | <.001 | 2.07 (1.60–2.70) | <.001 |
| Drugs at V2 | ||||
| Suboptimal statin therapy | 2.18 (1.40–3.40) | .001 | 2.54 (1.56–4.14) | <.001 |
| Aspirin | 0.49 (0.28–0.86) | .013 | 0.23 (0.13–0.38) | <.001 |
| P2Y12 inhibitor | ∗ | ∗ | 0.66 (0.39–1.12) | NS (P = .12) |
| Beta blocker | 0.86 (0.53–1.42) | NS (P = .56) | 0.76 (0.43–1.34) | NS (P = .34) |
| ACEI/ARB | 1.46 (0.84–2.55) | NS (P = .18) | 1.16 (0.63–2.13) | NS (P = .63) |
| Warfarin | 2.23 (1.13–4.42) | .022 | 2.94 (1.41–6.13) | .004 |
| Proton pump inhibitor | 0.97 (0.67–1.42) | NS (P = .89) | 1.40 (0.90–2.18) | NS (P = .14) |
ACEI, angiotensin-converting enzyme inhibitor; ACM, all-cause mortality; ARB, angiotensin II receptor blocker; BMI, body mass index; CABG, coronary artery bypass graft surgery; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; HR, hazard ratio; MACE, major adverse cardiovascular events; NSTE-ACS, non-ST elevation acute coronary syndrome; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.
Visit 2 P2Y12 status did not meet the proportional hazards assumption for MACE, and patient sex did not meet the proportional hazards assumption for ACM; these variables were considered in sensitivity analyses (see eTables 5, 8, 9 in the Supplement).